drugset / Trial / NCT02200822
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
RandomizedFactorialOpen-labelTreatment
Summary
The primary objective of this study is to demonstrate that in patients with recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%, after implantation of cardiac resynchronization therapy, device treatment is sufficient and neurohumoral blocker therapy can safely be withdrawn
Timeline
- Start
- 2014-07
- Primary completion
- 2019-02
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bisoprolol | Other / unclassified | 10 mg | — |
| Comparator | Candesartan | Unknown | 32 mg | — |
| Comparator | Captopril | Small molecule | 50 mg | — |
| Comparator | Carvedilol | Other / unclassified | 50 mg | — |
| Comparator | Enalapril | Other / unclassified | 10 mg | — |
| Comparator | Eplerenone | Unknown | 25 mg | — |
| Comparator | LISINOPRIL ANHYDROUS | Small molecule | 20 mg | — |
| Comparator | Metoprolol | Other / unclassified | 200 mg | — |
| Comparator | Nebivolol | Other / unclassified | 10 mg | — |
| Comparator | Ramipril | Small molecule | 10 mg | — |
| Comparator | Spironolactone | Small molecule | 25 mg | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |